GOVX
GeoVax Labs, Inc.
Overview
GeoVax Labs develops vaccines and immunotherapies against infectious diseases and solid tumors using proprietary MVA-based platforms. The company's lead program, GEO-MVA, is a Modified Vaccinia Ankara vaccine candidate for mpox and smallpox advancing toward Phase 3 trials in Europe.
GeoVax Labs, Inc is a Healthcare company operating in Biotechnology with a $7.0M market cap.
GOVX missed consensus EPS by 1.0% in Q1 FY2026, reported Mar 30, 2026.
18 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q3 FY2025Earnings2025-11-139 Q&A exchanges
- Q2 FY2025Earnings2025-07-2818 Q&A exchanges
- Q1 FY2025Earnings2025-05-0110 Q&A exchanges
- Q4 FY2024Earnings2025-03-2711 Q&A exchanges
- Q3 FY2024Earnings2024-11-1224 Q&A exchanges
- Q1 FY2024Earnings2024-05-146 Q&A exchanges
- Q4 FY2023Earnings2024-03-0121 Q&A exchanges
- Q3 FY2023Earnings2023-11-084 Q&A exchanges
- Q2 FY2023Earnings2023-08-0913 Q&A exchanges
- Q1 FY2023Earnings2023-05-0713 Q&A exchanges
- Q4 FY2022Earnings2023-03-2326 Q&A exchanges
- Q3 FY2022Earnings2022-11-0912 Q&A exchanges
- Q2 FY2022Earnings2022-08-0313 Q&A exchanges
- Q1 FY2022Earnings2022-04-2710 Q&A exchanges
- Q4 FY2021Earnings2022-03-0912 Q&A exchanges
- Q3 FY2021Earnings2021-11-1113 Q&A exchanges
- Q2 FY2021Earnings2021-08-1111 Q&A exchanges
- Q1 FY2021Earnings2021-05-0913 Q&A exchanges
History
Earnings history
- Q1 FY20262026-03-30EPS$-2.62 vs $-0.84-100.0%Rev$0 vs ——EODHD
- Q4 FY20252025-12-30EPS— vs $-5.35—Rev$0 vs ——EODHD
- Q3 FY20252025-11-12EPS$-0.31 vs $-0.29-6.9%Rev$0 vs ——EODHD
- Q2 FY20252025-07-27EPS$-0.35 vs $-0.30-16.7%Rev$852.3K vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.45 vs $-0.66+31.6%Rev$1.6M vs ——EODHD
- Q4 FY20242025-02-25EPS$-0.30 vs $-0.77+60.9%Rev$864.4K vs ——EODHD
- Q3 FY20242024-11-05EPS$-0.91 vs $-1.48+38.5%Rev$2.8M vs ——EODHD
- Q2 FY20242024-08-05EPS$-1.99 vs $-3.36+40.8%Rev$300.7K vs ——EODHD
- Q1 FY20242024-05-13EPS$-2.47 vs $-5.56+55.6%Rev$0 vs ——EODHD
- Q4 FY20232024-02-28EPS$-13.60 vs $-2.78-100.0%Rev$103.9K vs ——EODHD
- Q3 FY20232023-11-07EPS$-0.32 vs $-0.24-33.3%Rev$0 vs ——EODHD
- Q2 FY20232023-08-08EPS$-0.22 vs $-0.16-37.5%Rev$0 vs ——EODHD
- Q1 FY20232023-05-03EPS$-0.15 vs $-0.20+25.0%Rev$-81.5K vs ——EODHD
- Q4 FY20222023-03-22EPS$-0.20 vs $-0.200.0%Rev$-81.5K vs ——EODHD
- Q3 FY20222022-11-08EPS$-0.17 vs $-0.12-41.7%Rev$0 vs ——EODHD
- Q2 FY20222022-08-02EPS$-0.18 vs $-0.32+43.8%Rev$0 vs ——EODHD
- Q1 FY20222022-04-26EPS$-0.34 vs $-0.31-9.7%Rev$81.5K vs ——EODHD
- Q4 FY20212022-03-08EPS$-2.23 vs $-0.40-100.0%Rev$165.0K vs ——EODHD
- Q3 FY20212021-11-10EPS$-0.31 vs $-0.37+16.2%Rev$30.4K vs ——EODHD
- Q2 FY20212021-08-10EPS$-0.21 vs $-0.43+51.2%Rev$79.7K vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-03-30 | $-2.62 | $-0.84 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | — | $-5.35 | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.31 | $-0.29 | -6.9% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-07-27 | $-0.35 | $-0.30 | -16.7% | $852.3K | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.45 | $-0.66 | +31.6% | $1.6M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.30 | $-0.77 | +60.9% | $864.4K | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.91 | $-1.48 | +38.5% | $2.8M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-1.99 | $-3.36 | +40.8% | $300.7K | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-2.47 | $-5.56 | +55.6% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $-13.60 | $-2.78 | -100.0% | $103.9K | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-0.32 | $-0.24 | -33.3% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.22 | $-0.16 | -37.5% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.15 | $-0.20 | +25.0% | $-81.5K | — | — | EODHD |
| Q4 FY2022 | 2023-03-22 | $-0.20 | $-0.20 | 0.0% | $-81.5K | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.17 | $-0.12 | -41.7% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $-0.18 | $-0.32 | +43.8% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-04-26 | $-0.34 | $-0.31 | -9.7% | $81.5K | — | — | EODHD |
| Q4 FY2021 | 2022-03-08 | $-2.23 | $-0.40 | -100.0% | $165.0K | — | — | EODHD |
| Q3 FY2021 | 2021-11-10 | $-0.31 | $-0.37 | +16.2% | $30.4K | — | — | EODHD |
| Q2 FY2021 | 2021-08-10 | $-0.21 | $-0.43 | +51.2% | $79.7K | — | — | EODHD |
Source: EODHD. GOVX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks GOVX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $4.52 | $3.37 | +34.1% | +6.2% | +6.0% |
| Q4 FY2025 | $4.67 | $3.29 | +41.8% | +6.3% | +4.8% |
| Q3 FY2025 | $4.80 | $3.41 | +40.8% | +6.4% | +5.1% |
| Q2 FY2025 | $4.29 | $3.26 | +31.7% | +5.9% | +7.0% |
| Q1 FY2024 | $4.48 | $3.41 | +31.4% | -4.7% | -3.8% |
| Q4 FY2024 | $4.96 | $3.49 | +42.2% | -2.1% | -0.6% |
| Q3 FY2024 | $4.36 | $3.29 | +32.5% | +5.8% | +7.8% |
| Q2 FY2024 | $4.55 | $3.41 | +33.4% | -0.6% | +0.3% |
| Q1 FY2023 | $4.73 | $3.48 | +36.0% | +3.3% | +5.6% |
| Q4 FY2023 | $4.59 | $3.35 | +37.0% | +0.2% | +2.5% |
Guidance change history
Sample- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
- Q1 FY2024Raised2024-04-15
- Q4 FY2024Raised2024-13-15
- Q3 FY2024Raised2024-10-15
- Q2 FY2024Raised2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- David A DoddCEO2 yr 10 mo17 callsCurrentSample
CEO since 2023 • 3/8 beats (38%) • last call held guidance Q1 FY2025
- Mark ReynoldsCFO2 yr 10 mo18 callsCurrentSample
CFO since 2023 • 5/8 beats (63%) • guidance suspended Q1 FY2025
- Mark J NewmanChief Scientific Officer1 yr 10 mo10 callsCurrentSample
OTHER_C_SUITE since 2024 • 3/4 beats (75%) • last guidance raise Q1 FY2025
- Kelly T McKee JrChief Medical Officer2 yr 9 mo12 callsCurrentSample
OTHER_C_SUITE since 2023 • 6/8 beats (75%) • last call held guidance Q1 FY2025
- John W SharkeyVP, Business Development1 yr 10 mo13 callsCurrentSample
OTHER since 2024 • 1/4 beats (25%) • guidance suspended Q3 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GOVX.
$ curl https://api.spokenalpha.com/v1/companies/GOVXFAQ
Frequently asked about GOVX
Where can I find GeoVax Labs, Inc.'s (GOVX) earnings call transcripts?
Spoken Alpha indexes GOVX's earnings call transcripts at https://spokenalpha.com/companies/GOVX. Each call links to attributed speakers and parsed analyst Q&A.
When was GeoVax Labs, Inc.'s most recent earnings call?
GeoVax Labs, Inc. (GOVX) held its most recent earnings call on 2025-11-13, covering fiscal Q3 2025.
What sector is GOVX in?
GeoVax Labs, Inc. (GOVX) operates in the Healthcare sector (Biotechnology industry).